Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder

European Neuropsychopharmacology

Volumn 17, Issue 9, 2007, Pages 573-579

  Brundin, Lena ^a   Björkqvist, Maria ^b   Petersén, Åsa ^b   Träskman Bendz, Lil ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

CSF; Depression; Hypocretin; Hypothalamus; Orexin; Suicide

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; CHLORAL HYDRATE; CORTICOTROPIN RELEASING FACTOR; DELTA SLEEP INDUCING PEPTIDE; DIAZEPAM; FLUNITRAZEPAM; LEPTIN; LORAZEPAM; NITRAZEPAM; OREXIN A; OXAZEPAM; SOMATOSTATIN; THYROTROPIN; VASOPRESSIN; ZOPICLONE;

ADJUSTMENT DISORDER; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DYSTHYMIA; HUMAN; HYPOTHALAMUS; IMMUNOREACTIVITY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NEUROBIOLOGY; PRIORITY JOURNAL; SUICIDE; SUICIDE ATTEMPT; THYROTROPIN BLOOD LEVEL;

ADJUSTMENT DISORDERS; ADULT; AGE FACTORS; CORTICOTROPIN-RELEASING HORMONE; DELTA SLEEP-INDUCING PEPTIDE; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; DYSTHYMIC DISORDER; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; RADIOIMMUNOASSAY; SEX FACTORS; SOMATOSTATIN; STATISTICS, NONPARAMETRIC; SUICIDE;

EID: 34447531745     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.01.005     Document Type: Article

References (37)

1. Allard J.S., Tizabi Y., Shaffery J.P., Trouth C.O., and Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 38 (2004) 311-315
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. (1987), American Psychiatric Press, Washington, DC
3. Asberg M., Montgomery S., Perris C., Schalling D., and Sedvall G. CPRS-the comprehensive psychopathological rating scale. Acta Psychiatr. Scand., Suppl. 271 (1978) 5-27
4. Baumann C.R., Dauvilliers Y., Mignot E., and Bassetti C.L. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur. Neurol. 52 (2004) 73-76
5. Baumann C.R., Stocker R., Imhof H.G., Trentz O., Hersberger M., Mignot E., and Bassetti C.L. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 65 (2005) 147-149
6. Beck A.T., Davis J.H., Frederick C.J., Perlin S., Pokorny A.D., and Schulman R.E. Classification and nomenclature. In: Resnik H.L.P., and Hathorne B.C. (Eds). Suicide prevention in the seventies (1973), Superintendent of Documents, U.S. Government Printing Office, Washington DC 7-12
7. Bertolote J.M., Fleischmann A., De Leo D., and Wasserman D. Psychiatric diagnoses and suicide: revisiting the evidence. Crisis 25 (2004) 147-155
8. Brundin L., Petersén Å., Bjorkqvist M., and Traskman-Bendz L. Orexin and psychiatric symptoms in suicide attempters. J. Affect. Disord. (2006) (Electronic publication ahead of print)
9. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., and Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
10. Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Creange A., Remy P., Goldenberg F., and d'Ortho M.P. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61 (2003) 540-543
11. Dugovic C., Solberg L.C., Redei E., Van Reeth O., and Turek F.W. Sleep in the Wistar-Kyoto rat, a putative genetic animal model for depression. NeuroReport 11 (2000) 627-631
12. Geracioti Jr. T.D., Orth D.N., Ekhator N.N., Blumenkopf B., and Loosen P.T. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J. Clin. Endocrinol. Metab. 74 (1992) 1325-1330
13. Grady S.P., Nishino S., Czeisler C.A., Hepner D., and Scammell T.E. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep 29 (2006) 295-297
14. Holsboer F., Lauer C.J., Schreiber W., and Krieg J.C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62 (1995) 340-347
15. Kok S.W., Roelfsema F., Overeem S., Lammers G.J., Strijers R.L., Frolich M., Meinders A.E., and Pijl H. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J. Clin. Endocrinol. Metab. 11 (2002) 5085-5091
16. Kovalzon V.M., and Strekalova T.V. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J. Neurochem. 97 (2006) 303-309
17. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., and Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
18. Manaye K.F., Lei D.L., Tizabi Y., Davila-Garcia M.I., Mouton P.R., and Kelly P.H. Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J. Neuropathol. Exp. Neurol. 64 (2005) 224-229
19. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., Okun M., Rogers W., Brooks S., and Mignot E. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 50 (2001) 381-388
20. Nishino S., Ripley B., Mignot E., Benson K.L., and Zarcone V.P. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 110 (2002) 1-7
21. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., Pedrazzoli M., Padigaru M., Kucherlapati M., Fan J., Maki R., Lammers G.J., Bouras C., Kucherlapati R., Nishino S., and Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6 (2000) 991-997
22. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., Di Monte D., Dohi K., Melberg A., Lammers G.J., Nishida Y., Roelandse F.W., Hungs M., Mignot E., and Nishino S. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57 (2001) 2253-2258
23. Sakamoto F., Yamada S., and Ueta Y. Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. Regul. Pept. 118 (2004) 183-191
24. Salomon R.M., Ripley B., Kennedy J.S., Johnson B., Schmidt D., Zeitzer J.M., Nishino S., and Mignot E. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54 (2003) 96-104
25. Saper C.B., Scammell T.E., and Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437 (2005) 1257-1263
26. Schoenenberger G.A. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur. Neurol. 23 (1984) 321-345
27. Singareddy R.K., and Balon R. Sleep and suicide in psychiatric patients. Ann. Clin. Psychiatry 13 (2001) 93-101
28. Spinazzi R., Andreis P.G., Rossi G.P., and Nussdorfer G.G. Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol. Rev. 58 (2006) 46-57
29. Steiger A. Neurochemical regulation of sleep. J. Psychiatr. Res. (2006) (Electronic publication ahead of print)
30. Swaab D.F., Bao A.M., and Lucassen P.J. The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 4 (2005) 141-194
31. Taheri S., Gardiner J., Hafizi S., Murphy K., Dakin C., Seal L., Small C., Ghatei M., and Bloom S. Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats. NeuroReport 12 (2001) 459-464
32. Traskman L., Asberg M., Bertilsson L., and Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry 38 (1981) 631-636
33. Traskman-Bendz L., Ekman R., Regnell G., and Ohman R. HPA-related CSF neuropeptides in suicide attempters. Eur. Neuropsychopharmacol. 2 (1992) 99-106
34. Vankova J., Stepanova I., Jech R., Elleder M., Ling L., Mignot E., Nishino S., and Nevsimalova S. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 26 (2003) 427-430
35. Westling S., Ahren B., Traskman-Bendz L., and Westrin A. Low CSF leptin in female suicide attempters with major depression. J. Affect. Disord. 81 (2004) 41-48
36. Westrin A. Stress system alterations and mood disorders in suicidal patients. Biomed. Pharmacother. 54 (2000) 142-145
37. Winsky-Sommerer R., Yamanaka A., Diano S., Borok E., Roberts A.J., Sakurai T., Kilduff T.S., Horvath T.L., and de Lecea L. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J. Neurosci. 24 (2004) 11439-11448